Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Bestrijding van de ziekte van Alzheimer door slaap en lichaamsbeweging (CASE)

23 oktober 2026 bijgewerkt door: Azizi Seixas, University of Miami

Bestrijding van de ziekte van Alzheimer door slaap en lichaamsbeweging (CASE)

The Combating Alzheimer's through Sleep and Exercise (CASE) study is an exploratory, hypothesis-generating trial designed to: (1) assess whether improvements in sleep are associated with improvements in cognitive performance and cardiovascular and metabolic health; (2) evaluate the effects of structured, moderate-level aerobic and anaerobic exercise on cognitive performance and cardiovascular and metabolic health; (3) examine the combined, potentially synergistic effects of both interventions on cognitive performance and cardiovascular and metabolic health; and (4) investigate the role of light exposure as a potential modulator of sleep parameters.

Studie Overzicht

Studietype

Ingrijpend

Inschrijving (Geschat)

60

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Contact Back-up

Studie Locaties

    • Florida
      • Miami, Florida, Verenigde Staten, 33136
        • Werving
        • University of Miami Hospitals
        • Contact:
        • Hoofdonderzoeker:
          • Azizi A Seixas, PhD
        • Onderonderzoeker:
          • Alberto Ramos, MD
        • Contact:
        • Onderonderzoeker:
          • Debbie Chung, PhD

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

55 jaar tot 80 jaar (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Ja

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  1. Aged 55-80 years at the time of the screening visit
  2. Able to ambulate safely and independently
  3. Able to safely perform moderate-intensity exercise as per the Physical Activity Readiness Questionnaire (PAR-Q, a validated exercise readiness questionnaire)
  4. Able to wear and use Fitbit wristwatch and/or the Elemind Neuromodulation headband and Lys devices
  5. Able to operate a digital device like mobile phone or computer
  6. Able and willing to provide venous blood samples
  7. Able to understand and speak English (our AR-based MCI diagnosis tool does not yet have capacity for other languages)
  8. Able to self-report a history of cognitive changes or impairment
  9. Be cognitively able (including those with and without MCI) and willing to provide informed consent
  10. Body weight <400 pounds (<181.4kg) in order to safely operate the NuStep T4r Recumbent Stepper stationary bicycle

Exclusion Criteria:

  1. Severe mobility limitations that prevent safe participation in moderate exercise protocols
  2. Unstable or uncontrolled medical conditions (e.g., recent cardiovascular event (<6 months), cerebrovascular accident or transient ischemic attack (<6 months), active cancer, or uncontrolled diabetes) that pose safety concerns
  3. Inability to complete intake screening procedures
  4. Severe uncorrected hearing impairment-particularly if it precludes effective utilization of the Elemind Neuromodulation headband-and/or vision impairment that interferes with digital device usage or in-person exercise guidance
  5. Determined to have Alzheimer's/dementia based on performance on the Quick Mild Cognitive Impairment (QMCI).
  6. Inability or unwillingness to learn or engage with digital devices (e.g., smartphone, Fitbit, Elemind, or Lys), even with staff support
  7. Regular pre-study engagement in ≥150 minutes of moderate-level and/or ≥75 minutes of vigorous-level exercise per week based on Fitbit data obtained during the initial seven-day onboarding screening period
  8. Determined to have sufficient sleep, as defined by a sleep efficiency mean of ≥80%) based on Elemind Neuromodulation headband data obtained during the initial seven-day onboarding screening period
  9. Current usage of disease-modifying therapy targeting amyloid (e.g., anti-amyloid monoclonal antibodies) or tau
  10. Body weight ≥400 pounds (≥181.4kg), which would pose a safety risk during the operation of the NuStep recumbent stationary bicycle

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Preventie
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Sleep Only Group

Participants in this group will wear the Elemind headband 3-4 times weekly for 8 weeks.

The Elemind Neuromodulation headband is a wearable device that utilizes noninvasive, electroencephalography-based (EEG-based) technology to induce a sleep state more rapidly via personalized acoustic stimulation. Specifically, the headband uses a closed-loop system, meaning that the headband conveys stimulation based upon recorded neural activity in order to modulate real-time oscillating circuits at the macroscopic level. This device uses five dry, flexible EEG electrodes-including three recording electrodes that are positioned at the Fpz and Fp1/2 electrode sites in accordance with the 10-20 International System of electrode placement and two silicone rubber-based, linked reference electrodes located at the mastoids-to measure neural activity during sleep and provide an estimation of the phases of real-time neural oscillations. The headband generates a sound pulse by identifying alpha neural oscillations in real-time through endpoint-corrected Hilbert Transform algorithm.

Actieve vergelijker: Exercise Only Group

Participants in this group will participate in a structured, on-site, twice a week exercise program for 60 minutes/session for 8 weeks (16 total sessions). Each exercise session is comprised of 60 minutes, including 10 minutes of warm-up, 20 minutes of cardiovascular exercise on a stationary bike, 20 minutes of resistance training (1 day of upper body focus, 1 day of lower body focus each week), and 10 minutes of cooling off).

Participants randomized to the exercise-only group will engage in an 8-week, home- and site-based exercise intervention designed for older adults across a range of cognitive and physical function levels. All site-based sessions will occur in-person at the study facility under supervision of trained staff. Each week, participants will attend two 60-minute structured exercise sessions, consisting of aerobic training and resistance training. On the remaining five days when subjects will not engage in structured exercise, subjects will be asked to engage in 30 minutes of moderate-intensity walking activities. In-lab exercise protocols will be fully standardized to ensure consistency of exercise dosage and fidelity across participants. The target exercise load will be 270 minutes of moderate-intensity exercise weekly for 8 weeks.

Actieve vergelijker: Exercise and Sleep Group

Participants in this group will take part in the on-site, structured exercise program twice per week for 8 weeks in additional to wearing the Elemind headband 3-4 times per week for 8 weeks.

The Elemind Neuromodulation headband is a wearable device that utilizes noninvasive, electroencephalography-based (EEG-based) technology to induce a sleep state more rapidly via personalized acoustic stimulation. Specifically, the headband uses a closed-loop system, meaning that the headband conveys stimulation based upon recorded neural activity in order to modulate real-time oscillating circuits at the macroscopic level. This device uses five dry, flexible EEG electrodes-including three recording electrodes that are positioned at the Fpz and Fp1/2 electrode sites in accordance with the 10-20 International System of electrode placement and two silicone rubber-based, linked reference electrodes located at the mastoids-to measure neural activity during sleep and provide an estimation of the phases of real-time neural oscillations. The headband generates a sound pulse by identifying alpha neural oscillations in real-time through endpoint-corrected Hilbert Transform algorithm.

Participants randomized to the exercise-only group will engage in an 8-week, home- and site-based exercise intervention designed for older adults across a range of cognitive and physical function levels. All site-based sessions will occur in-person at the study facility under supervision of trained staff. Each week, participants will attend two 60-minute structured exercise sessions, consisting of aerobic training and resistance training. On the remaining five days when subjects will not engage in structured exercise, subjects will be asked to engage in 30 minutes of moderate-intensity walking activities. In-lab exercise protocols will be fully standardized to ensure consistency of exercise dosage and fidelity across participants. The target exercise load will be 270 minutes of moderate-intensity exercise weekly for 8 weeks.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Glycated Hemoglobin (HbA1c) Levels
Tijdsspanne: Up to Week 8

Measured from blood sample

Up to Week 8
Total Cholesterol Levels
Tijdsspanne: Up to Week 8

Measured from blood sample

Up to Week 8
Triglycerides Levels
Tijdsspanne: Up to Week 8

Measured from blood sample

Up to Week 8
High-sensitivity C-reactive protein (hs-CRP) Levels
Tijdsspanne: Up to Week 8

Measured from blood sample

Up to Week 8
Low-Density Lipoprotein (LDL) Levels
Tijdsspanne: Up to Week 8

Measured from blood sample

Up to Week 8
C-Peptides
Tijdsspanne: Up to Week 8

Measured from blood sample

Up to Week 8
High-Density Lipoprotein (HDL) Levels
Tijdsspanne: Up to Week 8

Measured from blood sample

Up to Week 8
Cognitive Function
Tijdsspanne: Up to 8 weeks

Cognitive function gauged from Altoida's Digital Neuro-Signatures

Up to 8 weeks
Insulin Levels
Tijdsspanne: Up to 8 weeks

Measured from blood sample

Up to 8 weeks
Neurofilament light chain
Tijdsspanne: Up to Week 8

Measured from blood sample

Up to Week 8

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Total Sleep Duration
Tijdsspanne: Up to Week 8

Measured from Elemind

Up to Week 8
Slow Wave Sleep Duration
Tijdsspanne: Up to Week 8

Measured from Elemind

Up to Week 8
%Slow-wave Sleep
Tijdsspanne: Up to Week 8

Measured by Elemind headband

Up to Week 8
Rapid Eye Movement Duration
Tijdsspanne: Up to Week 8

Measured by Elemind headband

Up to Week 8
%REM
Tijdsspanne: Up to Week 8

Measured by Elemind headband

Up to Week 8
Light Non-Rapid Eye Movement Duration
Tijdsspanne: Up to Week 8

Measured by Elemind headband

Up to Week 8
%Light Non-Rapid Eye Movement Sleep
Tijdsspanne: Up to Week 8

Measured by Elemind headband

Up to Week 8
Sleep Efficiency
Tijdsspanne: Up to Week 8

Measured by Elemind headband

Up to Week 8
Sleep Onset Latency
Tijdsspanne: Up to Week 8

Measured by Elemind headband

Up to Week 8
Restlessness (Restless Bouts/Hour during Sleep)
Tijdsspanne: Up to Week 8

Measured by Elemind headband

Up to Week 8

Andere uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Light Exposure
Tijdsspanne: Up to Week 8

Measured by LYS Device

Up to Week 8
Psychosocial Metrics
Tijdsspanne: Up to Week 8

Measured by Questionnaires

Up to Week 8

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Hoofdonderzoeker: Azizi A Seixas, PhD, University of Miami

Publicaties en nuttige links

De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

1 maart 2023

Primaire voltooiing (Geschat)

30 december 2028

Studie voltooiing (Geschat)

30 december 2028

Studieregistratiedata

Eerst ingediend

19 april 2021

Eerst ingediend dat voldeed aan de QC-criteria

19 april 2021

Eerst geplaatst (Werkelijk)

22 april 2021

Updates van studierecords

Laatste update geplaatst (Werkelijk)

27 oktober 2026

Laatste update ingediend die voldeed aan QC-criteria

23 oktober 2026

Laatst geverifieerd

1 oktober 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

product vervaardigd in en geëxporteerd uit de V.S.

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren